Fig. 5: Mpx-V3 immunogen protects BALB/c mice from skin pock lesions.
From: Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox
a Schematic of skin pock lesion challenge study with VACV Western Reserve strain. b Thermal profiling of the immunized mice following the tail scarification technique. All the groups, including normal control, adjuvant control, and Mpx-V3-immunized groups, were assessed for change in body temperature up to 21 days post-tail scarification by the VACV. The data shown here is each group’s mean ± standard error of the mean (SEM). c In the tail pock lesion challenge experiment, BALB/c mice were immunized with 25 μg of Mpx-V3 with AddaVaxTM or Alhydrogel. After prime and boost immunization, 21 days after the boost, mice were challenged with VACV (10 μL of 1 × 107 PFU/mL) vial tail scarification method as mentioned in the methods section. The appearance of “clinical signs” was evaluated on 6, 12, and 21 days post-tail scarification. The pictures shown in a red box represent the maximum intensity of skin lesions and scabs in adjuvant control groups, whereas the green box indicates the complete recovery in the Mpx-V3 immunized mice from the skin lesions and scabs.
